Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in Lymphangioleiomyomatosis (LAM)
NCT00005906Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2000
- Primary completion
- Apr 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in lymphangioleiomyomatosis (LAM), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Number of Participants With a Reduction in Total Tumor Volume of at Least 20% at 6 months and Number of Participants With a Reduction of Pain/Symptoms as Measured by a Simple Numeric Symptom Distress Scale (NDS) at 6 months. Started Jun 2000; status: completed.
02
Drugs
octreotide
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT00005906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005906.